Highlights
- 1Blood cancer discovery · 2023
- 2Blood · 2020
- 3Blood advances · 2020
Publications
Funding
Active
15 grants- KPBiomarkers of response in primary mediastinal B-cell lymphoma: Defining tumor microenvironment signaturesHyundai Hope on Wheels Foundation · 2024–2026HHWF 240412-01
- KPTargeting latency switch for the treatment of EBV-associated lymphomasAmerican Cancer Society · 2024–2026PF-23-1143526-01-IBCD
- Sub-PIAssessment of Clonal Hematopoiesis and Its Relationship to Cardiovascular Disease in Hodgkin Lymphoma SurvivorsU.S. Department of Defense · 2022–2026 · via Washington University, TheW81XWH-22-1-0665
- MPISensitizing Latency I EBV Lymphomas to Cytotoxic T Lymphocyte TherapyAmerican Society of Hematology Inc · 2025–2026ASH 250160-01
- KPSensitizing Latency I EBV Lymphomas to Cytotoxic T Lymphocyte TherapyLymphoma Research Foundation · 2025–2026LRF 244461-01
- Sub-PIAn Integrative Radiogenomic Framework for Predicting Treatment Failure in Adolescents & Young Adults with Hodgkin LymphomaU.S. Department of Defense · 2022–2026 · via Emory UniversityW81XWH-22-1-0338
- MPITargeting CD30 to enhance response to immune checkpoint blockade in Hodgkin LymphomaNational Cancer Institute · 2022–2026 · via Children's Oncology Group· 3 renewalsUG1CA233249-06
- Sub-PIA pilot study to evaluate ctDNA in PMBCLNational Cancer Institute · 2025–2026 · via Children's Oncology Group5 UG1 CA233249- 06
- Sub-PICOG Hodgkin Lymphoma (Defining Biomarkers of Response to Immunotherapy in Pediatric Hodgkin Lymphoma - The Jeffrey Pride Foundation Integrated Correlative Biology Awards)Jeffrey Pride Foundation INC · 2024–2026 · via Children's Oncology GroupNY018_2024_01_ROTH
- Sub-PIEvaluating Biologic Mechanisms of Racial and Ethnic Disparities in Pediatric Hodgkin LymphomaNational Cancer Institute · 2024–2026 · via Children's Oncology Group5 UG1 CA233249- 06
- Sub-PIOvercoming resistance to PD-1 Blockade in Hodgkin LymphomaNational Cancer Institute · 2024–2026 · via Children's Oncology Group5 UG1 CA233249- 06
- MPIRisk Stratification using Tumor Microenviroment Signatures in Hodgkin LymphomaChildren's Oncology Group · 2022–2026COG 222649-02
- MPICOG U10CA180886 PO: 0000004866National Cancer Institute · 2020–2026 · via Public Health Institute· 3 renewalsU10CA180886-11
Completed grants (13)
- PIBiomarkers Predictive of Antitumor Response in Primary Mediastinal B-cell LymphomaChildren's Oncology Group · 2022–2025COG 222665-01
- Sub-PIAHO1822 Study ChairMerck & Co., Inc. · 2020–2025 · via The Children’s Hospital of PhiladelphiaContractSA 203887-01
- Sub-PIGenomic and Immunologic Predictors of Response in Primary Mediastinal B-cell Lymphoma - The Jeffrey Pride Foundation Integrated Correlative Biology AwardsJeffrey Pride Foundation INC · 2024–2025 · via Children's Oncology GroupNY018_2024_02_ROTH
- PIDefining the evolution and tumor microenvironment interactions of classic Hodgkin lymphoma through single-cell multi-omics and genetically engineered mouse modelsStarr Cancer Consortium · 2022–2024SCC I15-0016
- PITargeting latent viral antigens in EBV+ Burkitt LymphomaHyundai Hope on Wheels Foundation · 2021–2024HHWF 215201-02
- PIModulation Of Viral Latency In EBV+ Lymphomas To Sensitize Tumors To ImmunotherapyAmerican Society of Hematology Inc · 2021–2023ASH 210413-02
- PIRational Translation of EZH2 Targeted Therapy in Germinal Center B-Cell LymphomaNational Cancer Institute · 2017–2021CareerK08CA219473-04
- PIWhy Personalized Medicine Fails: Shifting Focus to Genotype the Rare Cancer-initiating Cell in Hodgkin LymphomaThe Hartwell Foundation · 2019–2021THF 190511-01
- PIModulation of Viral Latency in EBV-Associated Lymphomas as a Mechanism to Sensitize Tumors to EBV-Directed Cellular TherapyStarr Cancer Consortium · 2018–2020I11-0043
- PIWhole exome and RNA sequencing of Hodgkin Reed-Sternberg cells isolated from pediatric Hodgkin lymphoma cases across COG sitesChildren's Oncology Group · 2019–2019COG 191520-01
- PITargeting the Hsp90 Oncoproteome in Pediatric Burkitt LymphomaSt. Baldrick's Foundation · 2015–2018SBF 170821-03
- MPIAMC Fellowship ProgramNational Cancer Institute · 2014–2015 · via University of California, Los Angeles
- MPIGenomic Biomarker Discovery in AIDS-Related Burkitt LymphomaNational Cancer Institute · 2014–2015 · via Sloan-Kettering Institute for Cancer ResearchP30CA008748-49 EW
Honors & distinctions
- Member · American Society for Clinical Investigation · 2023
Clinical research
Active
2 studies- PIBody Mass Index and the Development of Subsequent Malignant Neoplasms among Adolescent and Young Adult Cancer SurvivorsWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
- PIRetrospective multi-center study evaluating the benefit of consolidation with brentuximab vedotin following autologous stem cell transplant in pediatric patients with relapsed/refractory Hodgkin lymphomaMemorial Sloan Kettering Cancer Center · OPEN TO ACCRUAL (as of 2021)
Completed & closed trials (2)
- PICITY OF HOPE: A multicenter retrospective study of pediatric patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)City of Hope National Medical Center · CLOSED TO ACCRUAL (as of 2025)
- PINCT03407144An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)PHASE2 · Children's Oncology Group · IRB STUDY CLOSURE (as of 2023)Hodgkin Lymphoma
Available technologies
- Epigenetic Modifying Agents Sensitize EBV+ Lymphomas to ImmunotherapyApplication filedPoC DataPMID 32157281
News mentions
- Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better DiagnosticsApril 24, 2026
For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an “identity crisis.”
- Record Number of Weill Cornell Faculty Win ASCI Young Physician-Scientist AwardsMay 27, 2021
Eight Weill Cornell Medicine faculty members have received Young Physician-Scientist Awards from the American Society for Clinical Investigation (ASCI), the most awarded to any institution this year.
- Two Cornell Faculty Receive Hartwell Awards for Biomedical ResearchApril 17, 2019
Dr. Lisa Roth, assistant professor of pediatrics at Weill Cornell Medicine, and Dr. Bethany Cummings, assistant professor of biomedical sciences at the College of Veterinary Medicine, have each won a 2018 Hartwell Individual Biomedical Research Award, which will provide support for three years at $100,000 direct cost per year and designation as a Hartwell Investigator.
Mentoring
- KWKyle WierzbickiMD mentee · Class of 2025
External relationships
Other Interest
Gerson Lehrman Group (GLG) · Guidepoint Global LLC · Roche Pharmaceuticals, Inc. · Rosenblum Newfield, LLC
Other
Roche Pharmaceuticals, Inc.